UBS Maintains Neutral on AnaptysBio, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Neutral rating on AnaptysBio (NASDAQ:ANAB) but raises the price target from $23 to $33.
October 30, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Eliana Merle maintains a Neutral rating on AnaptysBio but raises the price target from $23 to $33, indicating a more optimistic outlook.
The increase in the price target from $23 to $33 suggests that UBS sees potential upside in AnaptysBio's stock, which could lead to positive investor sentiment and a potential short-term price increase. However, the Neutral rating indicates that UBS does not see a strong buy opportunity, balancing the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100